首页> 美国卫生研究院文献>Journal of Korean Medical Science >Outcomes of Controlled Ovarian Hyperstimulation/In Vitro Fertilization for Infertile Patients with Borderline Ovarian Tumor after Conservative Treatment
【2h】

Outcomes of Controlled Ovarian Hyperstimulation/In Vitro Fertilization for Infertile Patients with Borderline Ovarian Tumor after Conservative Treatment

机译:保守治疗后交界性卵巢肿瘤不育患者控制性过度刺激卵巢/体外受精的结果

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

To evaluate the outcomes of controlled ovarian hyperstimulation (COH)-in vitro fertilization (IVF) such as clinical pregnancy rate (CPR), implantation rate (IR) and live birth rate (LBR) for infertile patients with borderline ovarian tumor (BOT) after conservative treatment, 10 IVF cycles in five patients from January 1999 to July 2005 were analyzed. At the time of diagnosis with BOT, the mean age of patients was 30.0 yr (range, 22-40). For 8 cycles out of 10 attempted IVF cycles, except for 2 cancellation cycles, the mean number of oocytes retrieved was 5.6 (range, 2-16) with a mean fertilization rate of 74.4%. The CPR, IR, and LBR were 50.0% (4/8 cycles), 31.6% (6/19) and 50.0% (4/8 cycles) respectively. The mean follow-up period after COH-IVF initiation was 29.6 (range, 14-61) months. A gynecological oncologist followed all patients every 3 months during the first year and every 6 months thereafter. There was no recurrence during the follow-up period. Our results suggest that COH-IVF may be acceptable for infertile patients with BOT, especially in patients with early-stage BOT after conservative treatment.
机译:评估控制性卵巢过度刺激(COH)-体外受精(IVF)的结局,如临床交胎率(CPR),着床率(IR)和活产率(LBR),用于不育性交界性卵巢肿瘤(BOT)术后的患者保守治疗,分析了1999年1月至2005年7月期间5例患者的10个IVF周期。在诊断为BOT时,患者的平均年龄为30.0岁(范围22-40)。在10个尝试的IVF周期中的8个周期中,除2个取消周期外,回收的卵母细胞平均数为5.6(范围2-16),平均受精率为74.4%。 CPR,IR和LBR分别为50.0%(4/8个周期),31.6%(6/19)和50.0%(4/8个周期)。 COH-IVF启动后的平均随访时间为29.6(范围14-61)个月。在第一年中,妇科肿瘤科医生每3个月随访一次所有患者,此后每6个月随访一次。随访期间无复发。我们的结果表明,COH-IVF对于不育的BOT患者尤其是保守治疗后早期BOT的患者可能是可接受的。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号